American Society of Nephrology Annual Meeting
American Society of Nephrology Annual Meeting
November 11, 2019
3 min watch

VIDEO: Canagliflozin protects kidney function across GFR-spectrum

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

WASHINGTON — In a secondary analysis of the CREDENCE trial presented here at ASN Kidney Week, researchers focused on subgroups of different GFRs. They determined canagliflozin is safe and effective even for patients with eGFR of 30 mL/min/1.73m2 to less than 45 mL/min/1.73m2.

“The bottom line is that the benefit is clearly not glucose dependent and certainly not diuretic dependent,” George L. Bakris, MD, FASN, FAHA, professor of medicine and director of the American Heart Association’s Comprehensive Hypertension Center at the University of Chicago Medicine, told Healio Nephrology in a video exclusive. “This drug protects the kidney across all spectrum of GFR down to stage 4 CKD and provides cardiovascular risk reduction, especially [for] heart failure.”